"The controversy surrounding authorised generic/pseudo-generic drugs these days is very much in the air in the United states and Canada, especially in relation to the antitrust concerns that arise from them. However, there is very little literature on the subject, especially in UK/Europe.Although he has seen some newsy items on the subject, this member of the IPKat team can't think of any legal analysis that he could confidently recommend, so he wonders if his readers - especially those from the pharmaceutical sector - can make any suggestions. Adds Merpel, if there are any people out there who are currently writing on the topic and want to share their thoughts with others, perhaps through the medium of this weblog we can make some contacts. The IPKat's email address is email@example.com and he's (almost) always happy to hear from readers.
I have tried to find some material in the European context but have not been able to do so, I was wondering if you could guide me towards some reading materials".